| Detected | Trial | Change |
|---|---|---|
| 2026-08-11 | NCT03744390 IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome |
date change Completion pushed: 2026-03-18 -> 2026-12-18 |
| 2026-08-07 | NCT06670222 Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) |
date change Primary completion pushed: 2026-07 -> 2026-08-24 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03223961 | A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS | Myelodysplastic Syndromes | Active, Not Recruiting |
| Phase 2 | |||
| NCT07098936 | Momelotinib in VEXAS Syndrome | VEXAS Syndome | Recruiting |
| NCT05768711 | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic… | Chronic Myeloid Leukemia | Active, Not Recruiting |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Myelodysplastic Syndromes | Active, Not Recruiting |
| NCT03744390 | IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome | Myelodysplastic Syndromes | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05181735 | Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being… | MDS | Recruiting |
| NCT05226455 | Venetoclax in Patients With MDS or AML in Relapse After AHSCT | MDS | Active, Not Recruiting |
| NCT05782127 | Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk… | Untreated Myelodysplastic Syndrome | Active, Not Recruiting |
| Phase 1 | |||
| NCT06670222 | Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) | Low-risk Myelodysplastic Syndromes | Recruiting |
| Not specified | |||
| NCT06956755 | Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia | Myelodysplastic Syndromes | Recruiting |
| NCT02938858 | French Registry of First-line Treatment of Acute Promyelocytic Leukemia | Acute Promyelocytic Leukemia | Active, Not Recruiting |